Sanofi and Regeneron Finalizes the Restructuring of Their Collaboration on Praluent (alirocumab)
Shots:
- Sanofi has finalized the planned Praluent (alirocumab) restructuring with Regeneron. The new agreement is effective from Apr 01- 2020 that simplify the Ab collaboration b/w the companies- increases efficiency and streamlines operations for Praluent
- Sanofi will be solely responsible for Praluent outside the US while Regeneron will be responsible for Praluent in the US. Additionally- the companies entered into agreements to support manufacturing needs in the near term
- In Dec 2019- Sanofi intended to restructure its Ab collaboration for Praluent and Kevzara (sarilumab). Sanofi will continue to assess the restructuring related to Kevzara
Click here to read full press release/ article | Ref: Sanofi | Image: Owler
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
